项目整合精选

聚焦新型临床类新产品的整合与转化. 在创新药研发领域，传统的“单一产品、单打独斗”模式正在被一种更系统化的“项目整合”思维所取代。项目整合的核心，在于将散落在研发早期、中期的创新资产，通过资金、临床资源、产业生态等多维度要素的有机组合，实现从“科学发现”到“临床价值”，再到“商业成功”的跨越。研发与商业的战略整合：从“资产思维”到“组合思维”它要求我们超越单个分子的视野，拥抱一个由技术创新、临床需求、资本支持和商业洞察共同构成的复杂网络。在这个网络中，成功的标准不再是单一的“获批上市”，而是能否通过高效的整合，将科学上的突破，转化为临床上真正可及、商业上可持续、能够惠及患者的解决方案。近年来，药物发现已从传统的小分子化药拓展至更多元的分子类型，这些新型API在项目整合中呈现出独特的开发范式，项目整合的核心挑战在于递送系统的设计与肝外靶向能力的突破。
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

项目整合精选

KB-5246

Chemical Name: 9,1-Epoxymethano-7-fluoro-8-(4-methyl-1-piperazinyl)-5-oxo-5H-thiazolo[3,2-a]quinoline-4-carboxylic acid hydrochloride
CAS No. 119474-55-4, 119474-47-4 (free base)
项目整合开发状态: Phase...
参考文献标题:Quinolinecarboxylic acid derivs.,a compsns.comprising the same,process for preparing the same,and the use of the same for the manufacture of medicaments
文献作者:Taguchi,M.; Kondo,H.; Inoue,Y.; Kawahata,Y.; Tsukamoto,G.(Kanebo Pharmaceuticals,Ltd.)
参考来源:EP 0286089; JP 1989199979; US 4808584

D-19050

Chemical Name: 2-Amino-3-[(prop-1-en-3-yl)oxycarbonylamino]-6-(4-fluorobenzylamino)pyridine hydrochloride; Prop-1-en-3-yl [N-[2-amino-6-(4-fluorobenzylamino)pyridin-3-yl]]carbamate hydrochloride; 2-Am...
参考文献标题:D-19050
文献作者:Engel,J.; Emig,P.; Szelenyi,I.; Nickel,B.; Weischer,K.H.
参考来源:Drugs Fut 1989,14(6),511

CI-949

Chemical Name: 5-Methoxy-3-(1-methylethoxy)-1-phenyl-N-(1H-tetrazol-5-yl)-1H-indole-2-carboxamide L-arginine salt; 3-Isopropoxy-5-methoxy-1-phenyl-N-(1H-tetrazol-5-yl)-1H-indole-2-carboxamide L-argini...
参考文献标题:CI-949 AND RELATED INDOLECARBOXAMIDOTETRAZOLES: A NEW CLASS OF POTENTIAL ANTIALLERGY AGENTS
文献作者:Unangst,P.C.; Conroy,M.C.
参考来源:Drugs Fut 1990,15(10),1005

RG-12525

Chemical Name: 5-[2-[4-(Quinolin-2-ylmethoxy)phenoxymethyl]benzyl]-1H-tetrazole
CAS No. 120128-20-3
项目整合开发状态: Clinical
项目研究机构: Aventis Pharma (Originator)
合成路线:A synthesis of RG-12525 has ...
参考文献标题:Quinoline derivs.as antagonists of leukotriene D4,compsns.containing the same and processes for their preparation
文献作者:Huang,F.-C.; Galemmo Jr.,R.A.; Campbell,H.F.(Aventis Pharma SA)
参考来源:EP 0348155; EP 0784052; US 4920131

Pyriferone, BIM-15427

Chemical Name: 2-Amino-10-fluoro-4,5,6,7-tetrahydro-3H-benzo[6,7]cyclohepta[1,2-d]pyrimidin-4-one
CAS No. 121168-73-8
项目整合开发状态: Preclinical
项目研究机构: Biomeasure (Originator)
合成路线:The nitrati...
参考文献标题:Pyriferone
文献作者:Kim,S.H.
参考来源:Drugs Fut 1993,18(11),1009

BI-L-0093BS, BI-L-93 BS

Chemical Name: (E)-2,6-Di-tert-butyl-4-[2-(3-pyridinyl)ethenyl]phenol; (E)-3-[2-(3',5'-Di-tert-butyl-4'-hydroxyphenyl)ethenyl]pyridine
CAS No. 116376-62-6
项目整合开发状态: Preclinical
项目研究机构: Boehri...
参考文献标题:2,6-Disubstituted-4-(2-arylethenyl)phenol 5-lipoxygenase inhibitors: Development and profile of BI-L-239
文献作者:Lazer,E.S.; Farina,P.R.; Gundel,R.H.; Wegner,C.D.
参考来源:Drugs Fut 1991,16(7),641

Methoctramine

Chemical Name: N,N'-Bis[6-[(2-methoxybenzyl)amino]hexyl]-1,8-octanediamine tetrahydrochloride
CAS No. 104807-46-7
项目整合开发状态: Preclinical
项目研究机构: Universit?degli Studi di Bologna (Originator), ...
参考文献标题:METHOCTRAMINE
文献作者:Melchiorre,C.; Minarini,A.; Quaglia,W.; Tumiatti,V.
参考来源:Drugs Fut 1989,14(7),628

Y-26611

Chemical Name: 7-[2-(Aminomethyl)-4-morpholinyl]-1-cyclopropyl-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
CAS No. 122894-02-4, 122894-15-9 (HCl)
项目整合开发状态: Phase II
项目研究机构: Japa...
参考文献标题:Quinolonecarboxylic acid cpds.and pharmaceutical use thereof
文献作者:Araki,K.; Kuroda,T.; Uemori,S.; Moriguchi,A.; Ikeda,Y.(Welfide Corporation)
参考来源:EP 0311948; US 4889857

P16CM

Chemical Name: 11beta,17alpha,21-Trihydroxy-3,20-dioxopregna-1,4-diene-16alpha-carboxylic acid methyl ester; 11beta,17alpha,21-Trihydroxypregna-1,4-diene-3,20-dione-16alpha-carboxylic acid methyl este...
参考文献标题:Anti-inflammatory carboxy pregnane derivatives
文献作者:Lee,H.J.(Florida Agricultural and Mechanical Univ.)
参考来源:US 4762919; WO 8705028

YM-796

Chemical Name: (S)-(-)-2,8-Dimethyl-3-methylene-1-oxa-8-azaspiro[4.5]decane L-tartrate monohydrate
CAS No. 171252-80-5 ((R)-isomer, anhydrous D-tartrate), 132041-82-8 ((R)-isomer,anhydrous free bas...
参考文献标题:Heterocyclic spiro cpds.and their preparation
文献作者:Tsukamoto,S.-I.; Nagaoka,H.; Usuda,S.; Harada,M.; Tamura,T.(Yamanouchi Pharmaceutical Co.,Ltd.)
参考来源:AU 8823449; EP 0311313; JP 1990036183; US 4996210